Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.43 |
| ▸ | TUBB | P07437 | 3/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.43 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.43 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.43 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.43 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.43 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.43 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.43 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.43 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.43 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL322335 | 0.87 | MAPT (0.45) | MAPTSMN1; SMN2TP53 | |
| SCHEMBL2519397 | 0.86 | NPC1 (0.46) | MAPTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1573132 | 0.83 | MAPT (0.40) | MAPTTP53GAA | |
| SCHEMBL3602590 | 0.82 | NPC1 (0.40) | MAPTNPC1GAAATMRXFP1 | |
| SCHEMBL6220257 | 0.82 | HTT (0.43) | MAPTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1572852 | 0.81 | MAPT (0.42) | MAPTSMN1; SMN2TP53 | |
| SCHEMBL11186148 | 0.81 | MAPT (0.41) | MAPTTP53 | |
| SCHEMBL3944999 | 0.81 | MAPT (0.57) | MAPTSMN1; SMN2TP53GAA | |
| SCHEMBL4521306 | 0.80 | MAPT (0.40) | MAPTSMN1; SMN2TP53GAA | |
| SCHEMBL1572805 | 0.80 | MAPT (0.47) | MAPTSMN1; SMN2NPC1GAAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803811-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2010-09-28 | — | — | US | disclosed |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | US | disclosed |
| US-7442708-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-10-28 | — | — | US | disclosed |
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI (FR) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | FGFR3, FGFR1, NTRK3 | MAPT 4109/4885TUBB4A 2898/4885TUBB 2622/4885 |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | FGF2, FGF1, FGFR1 | MAPT 2866/4885TUBB4A 1990/4885TUBB 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.